Patents Examined by Sabiha N. Qazi
  • Patent number: 10806788
    Abstract: The present disclosure relates to novel chlorin-vitamin conjugates and method of making and using the chlorin-vitamin conjugates.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: October 20, 2020
    Assignee: Purdue Research Foundation
    Inventor: Meden Fruel Isaac-Lam
  • Patent number: 10793509
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are useful in the treatment of neoplastic diseases or proliferative disorders. The compounds are formulated into pharmaceutical compositions, which can be used in methods of treating neoplastic diseases or proliferative disorders The compounds are useful to treat cancers such as prostate, pancreatic, lung, skin, breast, bladder, colon, and blood cancers.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: October 6, 2020
    Assignee: UNIVERSITÄT ZU KOLN
    Inventors: Albrecht Berkessel, Mark Krüger, Karl-Anton Kreuzer, Simon Poll-Wolbeck
  • Patent number: 10780061
    Abstract: A method of increasing PGC-1? gene expression, decreasing PARIS gene expression, or promoting farnesylation of PARIS in a mammalian cell, the method comprising administering an effective amount of farnesol, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell; and related methods and compositions.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: September 22, 2020
    Assignee: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Sungchun Cho, Kyungho Kim, Euiseok Shin, Jongsun Kang, Jooho Shin, Juhyeon Bae, Hyeonju Jeong, Areum Jo, Sangchul Park
  • Patent number: 10766920
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 8, 2020
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Patent number: 10738005
    Abstract: Described herein are compositions and compounds having one or more aziridinyl groups, and methods of making the same. The compounds can also have one or more nitrogen atoms that each can be positively charged. The composition and compounds can inactivate one or more nucleic acid molecules (e.g. a DNA and/or a RNA from a pathogen) in a sample. The sample can comprise a blood or blood product (e.g., donated blood). The compositions and compounds can inactivate any nucleic acid present in a blood or blood product, thereby making the blood or blood product safe for use (e.g., in a transfusion).
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 11, 2020
    Assignee: ZATA Pharmaceuticals, Inc.
    Inventor: David R. Tabatadze
  • Patent number: 10738075
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: August 11, 2020
    Assignee: Evestra, Inc.
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • Patent number: 10723694
    Abstract: Propargyl-functionalized macrocyclic compounds can include non-aggregating compounds having at least one phthalocyanine (Pc), azaphthalocyanine (AzaPc), or naphthalocyanine (Nc) unit. The compounds can be metal-free or metal-complexed. The metal-complexed compounds can include zinc (II), for example. The compounds can include multiple propargyl moieties at different sites, e.g., peripheral or non-peripheral sites, as described herein. Exemplary compounds include an azaphthalocyanine complex (AzaPc1) and phthalocyanine complexes (Pc2-Pc5). The compounds may provide efficient solubility in aqueous and/or organic solvents, optimal physicochemical properties, improved photo-sensitizability, significant tumor specificity, and electron transfer tunability. The compounds can provide suitable non-aggregated molecular scaffolds for construction of numerous macrocycle derivatives via different organic transformation methodologies, e.g., Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC).
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: July 28, 2020
    Assignee: Kuwait University
    Inventors: Saad A. Makhseed, Ali A. Husain, Asaithampi Ganesan, Mahmut Durmus
  • Patent number: 10716798
    Abstract: A pharmaceutical composition for tranquilizing cardiomyocytes present in heart muscle in a subject diagnosed with a cardiac overload disease comprises a therapeutically effective amount of a Vitamin D5 compound and a pharmaceutically acceptable excipient. A method for treating or preventing heart failure in a subject diagnosed as having heart failure or being at risk for heart failure, comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a Vitamin D5 compound and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: July 21, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Robert U. Simpson
  • Patent number: 10716797
    Abstract: The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): There are provided compositions and kits using such compounds and inhibitors.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: July 21, 2020
    Assignee: SOCPRA SCIENCES ET GÉNIE S.E.C.
    Inventors: Éric Marsault, François Malouin, Félix Chagnon, Isabelle Guay, Simon Boulanger
  • Patent number: 10716795
    Abstract: Provided are steroid analogues functionalized with polar substituents at the C3 and/or C20 positions of the steroid ring system that exhibit improved water solubility. Also provided are pharmaceutical compositions comprising the steroid analogues and methods using the novel steroid analogues for the treatment and prevention of neurodegeneration in a patient following injury to the central nervous system.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: July 21, 2020
    Assignee: Emory University
    Inventors: Christopher MacNevin, Donald G. Stein, Dennis C. Liotta, Iqbal Sayeed, David B. Guthrie, Mark A. Lockwood, Michael G. Natchus
  • Patent number: 10660874
    Abstract: An isolated or synthesized compound of Formula I and salts thereof are provided. A compound isolated from Actinomadura and having a chemical formula of C38H60O12 is also provided. Compositions including the compounds and methods of using the compounds to treat bacterial infections including gram positive infections such as C. difficile are also disclosed.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: May 26, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Timothy Scott Bugni, Thomas Philip Wyche, Douglas R. Braun, Jeffrey S. Piotrowski, Nasia Safdar
  • Patent number: 10654810
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 19, 2020
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 10638755
    Abstract: Suggested is a antimicrobial agent An antimicrobial composition comprising (a) at least one acetophenone derivative of formula (I) in which R1 stands for hydrogen or methyl, and R2 stands for hydrogen, hydroxyl or a —OCH3 group, or a cosmetically or pharmaceutically acceptable salt thereof, and (b) at least one second antimicrobial agent.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: May 5, 2020
    Assignee: Symrise AG
    Inventors: Manuel Pesaro, Bernd Hölscher, Gerhard Schmaus, Antje Köhler
  • Patent number: 10626112
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: April 21, 2020
    Assignee: EA PHARMA CO., LTD.
    Inventors: Kaori Kobayashi, Tamotsu Suzuki, Tomohiro Fujii, Tatsuya Okuzumi
  • Patent number: 10568893
    Abstract: Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: February 25, 2020
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Carl Genberg
  • Patent number: 10548895
    Abstract: The invention pertains to ligands that bind to CD81 and that inhibit or block Plasmodium attachment to CD81, compositions and methods for preventing, inhibiting or treating infection by Plasmodium and ligands that target a Plasmodium binding site on CD81 and methods of making and using them. A series of ligand binding sites on the large extracellular loop of the open conformation of CD81 have been identified. Several important sites were located in regions identified by mutational studies to be the site of Plasmodium binding. Ligands that recognize these sites were identified. Linking together two or three ligands that bind with low or moderate affinities to different structurally unique sites on a target protein were used to generate small molecule ligand conjugates that exhibit very high affinities to their CD81 targets. Hybrid ligand molecules were also designed using fragment-based drug design methods to generate analogs of the ligands that bind more tightly to the protein than the parent compounds.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: February 4, 2020
    Assignee: The American University in Cairo
    Inventors: Hassan Azzazy, Reem Al-Olaby, Rodney Balhorn
  • Patent number: 10543217
    Abstract: Disclosed is a method of treatment or prevention of frailty in an elderly patient, particularly having an age of 60 or older. The method provides the concomitant parenteral administration of a combination of an anabolic steroid and a vitamin D compound. A preferred combination comprises nandrolone decanoate and cholecalciferol (vitamin D3). The invention, in a further preference, provides a booster therapy to support frail elderly that have undergone hospitalization or surgery to retain independence and regain their regular physical and mental activities.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: January 28, 2020
    Assignee: Organext Research B.V.
    Inventors: Marjanna Prins, Helenius Jan Kloosterboer
  • Patent number: 10544090
    Abstract: Rhein analogues that exhibit anti-proliferative activity, particular against cancer cells, are described herein. In some embodiments, the compounds contain a flat or planar ring system. Such rings system by facilitate non-covalent binding of the compounds to the DNA complex, such as by intercalation. In some embodiment, the compounds contain a flat or planar ring system as described above and one or more substituents which are alkylating moieties, electrophilic groups or Michael acceptors or groups which contain one or more alkylating moieties, electrophilic groups and/or Michael acceptors. The compounds described herein can also contain one more functional groups to improve the solubility of the compounds.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: January 28, 2020
    Assignees: Georgia State University Research Foundation, Inc., Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Binghe Wang, Chaofeng Dai, Alexander Draganov, Xiaochuan Yang, Guojing Sun, Chunhao Yang, Weixuan Chen, Nanting Ni, Muxiang Zhou, Lubing Gu
  • Patent number: 10537541
    Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension. The compositions of such embodiments include activated fatty acids such as alkyl substituted fatty acids, keto fatty acids and nitro fatty acids. The methods of various embodiments include administering an effective amount of 10-nitro-9(E)-octadec-9-enoic acid to treat such diseases.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: January 21, 2020
    Assignee: Complexa Inc.
    Inventor: Diane Jorkasky
  • Patent number: 10532050
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Mickey L. Wells